|1.||Chen, Zuo: 8 articles (04/2010 - 12/2005)|
|2.||Ye, Ping: 5 articles (11/2014 - 10/2006)|
|3.||Li, Jian-Jun: 5 articles (04/2010 - 02/2005)|
|4.||Lu, Zong-Liang: 5 articles (04/2010 - 02/2005)|
|5.||Yu, Xue-Hai: 4 articles (04/2010 - 07/2007)|
|6.||Wu, Yang-Feng: 4 articles (04/2010 - 07/2007)|
|7.||Zhao, Yu-Cheng: 4 articles (04/2010 - 07/2007)|
|8.||Du, Bao-min: 4 articles (07/2007 - 12/2005)|
|9.||Lu, Zong-liang: 4 articles (02/2007 - 12/2005)|
|10.||Wu, Yang-feng: 4 articles (02/2007 - 12/2005)|
04/01/2010 - "Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS)."
01/01/2010 - "Long-term effects of Xuezhikang on blood pressure in hypertensive patients with previous myocardial infarction: data from the Chinese Coronary Secondary Prevention Study (CCSPS)."
08/01/2009 - "The purpose of this study, therefore, was to evaluate the impact of Xuezhikang on reducing cardiovascular events and mortality in elderly Chinese hypertensive patients with a history of myocardial infarction (MI) enrolled in the Chinese Coronary Secondary Prevention Study. "
08/01/2009 - "Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS)."
07/01/2007 - "Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study."
01/01/2012 - "Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia. "
11/01/2014 - "Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study."
01/01/2014 - "Randomized trials of RYR (not including Xuezhikang and Zhibituo) and placebo as control in patients with dyslipidemia were considered. "
01/01/2012 - "All randomized clinical trials (RCTs) with Xuezhikang as a treatment for CHD combined with dyslipidemia were considered for inclusion. "
10/01/2011 - "This study give screening of traditional Chinese medicine(TCM) symptoms item of post-marketing medicine Xuezhikang re-evaluation as example that reference to principle dyslipidemia clinical research, academic dissertations, Xuezhikang directions, clinical expert practice experience etc. while standardization those symptom names and screening 41 dyslipidemia common symptoms. "
|3.||Coronary Disease (Coronary Heart Disease)
10/01/2014 - "[Adjunctive therapy of xuezhikang capsule for coronary heart disease: a systematic review and meta-analysis of randomized controlled trials]."
05/01/2011 - "Clinical trials indicated that Xuezhikang with lipid-lowering action could reduce the risk of cardiac events and total mortality of Chinese coronary heart disease patients. "
04/01/2010 - "However, Xuezhikang treatment reduced the incidence of coronary events by 43.0% (P = 0.02), deaths from coronary heart disease (CHD) by 30.0% (P < 0.01), and all-cause mortality by 35.8% (P = 0.001). "
08/01/2009 - "Death from coronary heart disease (CHD) totaled 49 cases in the Xuezhikang group (6.4%) and 68 cases in the placebo group (9.0%), indicating that Xuezhikang significantly decreased the risk of CHD death by 29.2%. "
07/01/2007 - "To evaluate whether lipid-lowering therapy with xuezhikang reduces the risk of coronary events and total mortality in patients with coronary heart disease (CHD) aged 65 and older. "
|4.||Hypertension (High Blood Pressure)
07/01/2009 - "Long-term therapy with Xuezhikang improved LV diastolic function, probably mediated through antifibrotic and anti-inflammatory effects and independent of blood pressure and lipid profiles in patients with essential hypertension."
01/01/2015 - "In summary, the overexpression of Fibulin-3 and MMP-2, 9 levels were associated with hypertension and vascular remodeling and inhibited by Xuezhikang. "
07/01/2009 - "Potential protective effect of long-term therapy with Xuezhikang on left ventricular diastolic function in patients with essential hypertension."
01/01/2009 - "Effect of xuezhikang on alpha1- and beta2-microglobulin in patients with essential hypertension."
10/01/2006 - "Xuezhikang can reduce the cardiac events and mortality in CHD patients with or without hypertension."
01/01/2015 - "Therefore, more strictly designed large-scale randomized clinical trials are needed to evaluate the efficacy of Xuezhikang capsule in type 2 diabetes with hyperlipemia. "
01/01/2015 - "Xuezhikang capsule may be effective for treating type 2 diabetes with hyperlipemia. "
01/01/2015 - "To evaluate the efficacy and safety of Xuezhikang capsule treating type 2 diabetes with hyperlipidemia. "
01/01/2015 - "Xuezhikang Capsule for Type 2 Diabetes with Hyperlipemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trails."
05/01/2009 - "Two hundred and four patients of hyperlipidemia were randomly divided into a Fenglong group and a Xuezhikang group, 102 cases in each group. "
|1.||Non-alcoholic Fatty Liver Disease
|4.||red yeast rice
|8.||Interleukin-6 (Interleukin 6)
|10.||Endothelin-1 (Endothelin 1)
|1.||Acupuncture Points (Acupuncture Point)
|4.||Chinese Traditional Medicine (Traditional Chinese Medicine)